CVRx secures permanent Category I CPT codes for Barostim effective January 1, 2026 — removes largest reimbursement barrier
Summary
CVRx secured permanent Category I Current Procedural Terminology (CPT) codes for Barostim baroreflex activation therapy, which took effect January 1, 2026. Category I CPT codes are the standard billing codes used for established, widely performed medical procedures — replacing the temporary Category III codes that indicated Barostim was considered an "emerging technology" by payers. Permanent Category I status signals that the AMA CPT Editorial Panel has deemed Barostim therapy sufficiently evidence-based and widely used to merit standard coding. This enables straightforward standard reimbursement without case-by-case prior authorization that Category III codes typically require.
Why it matters
Permanent Category I CPT codes for Barostim is the reimbursement infrastructure milestone that enables scale commercial growth. Category III codes require payer-by-payer, often case-by-case prior authorization — a massive administrative burden that limits adoption even when coverage exists in principle. Category I removes this barrier: cardiologists can now implant Barostim and bill it the same way they bill any established cardiac procedure, without special authorization paperwork. This single regulatory change may do more for CVRx's growth than any clinical trial result.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial